Evidence map›Paper›PMID 32267998›Full record

ArticleJournal of thrombosis and haemostasis : JTH2020

Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.

Janice Wang, Negin Hajizadeh, Ernest E Moore, Robert C McIntyre, Peter K Moore, Livia A Veress, Michael B Yaffe, Hunter B Moore, Christopher D Barrett

3 registry-linked trialsOpen access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 323 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
323citing papers in PubMed, 6 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04433026 unknown statusnot on this map

B-natriuretic Peptide (BNP), Serum Troponin-I, and D-dimer as Risk Factors for In-hospital Death in Patients With COVID-19

TypeobservationalSponsorAssiut UniversityRan2020 to 2021Enrolled90ConditionsCOVID-19ArmsN terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I
NCT04777981 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Efficacy of Cannabidiol in Combination With Red Algae (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection PASC

TypeinterventionalSponsorAnewsha Therapeutics Inc.Ran2022 to 2022Enrolled60ConditionsCOVID-19, SARArmsCBDRA60 supplement, Placebo
NCT04900129 phase1completednot on this map

Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study

TypeinterventionalSponsorSher-E-Bangla Medical CollegeRan2020 to 2020Enrolled43ConditionsCovid19ArmsMenthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%
3 · Its place in the literature

Who cites it

323 citing papers in PubMed, 6 syntheses or guidelines pooled it, 559 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
    Article
  19. Article
  20. Article

263 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Janice WangFeinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
Negin HajizadehFeinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
Ernest E MooreDepartment of Surgery, Ernest E Moore Shock Trauma Center at Denver Health, Denver, CO, USA.
Robert C McIntyreDepartment of Surgery, University of Colorado Denver, Aurora, CO, USA.
Peter K MooreDepartment of Medicine, University of Colorado Denver, Aurora, CO, USA.
Livia A VeressDepartment of Pediatrics, Pulmonary Medicine, University of Colorado Denver, Aurora, CO, USA.
Michael B YaffeCenter for Precision Cancer Medicine, Departments of Biological Engineering and Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Hunter B MooreDepartment of Surgery, University of Colorado Denver, Aurora, CO, USA.
Christopher D BarrettCenter for Precision Cancer Medicine, Departments of Biological Engineering and Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-9720-8155
University of Colorado Denver · USBeth Israel Deaconess Medical Center · USNorthwell Health · USDenver Health Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.

Indexed as

Thrombolytic TherapyAgedBetacoronavirusBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Fatal OutcomeFemaleFibrinolysisFibrinolytic AgentsHost-Pathogen InteractionsHumansMaleMiddle AgedPandemicsPneumonia, ViralFibrinolytic AgentsTissue Plasminogen Activatoracute respiratory distress syndrome (ARDS)case reportCOVID-19fibrinolysistissue plasminogen activator (tPA)

Identifiers

PMID32267998
PMCPMC7262152
OpenAlexW3014627815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.